ophthalmology

Closeup of blue eye on black background

Biotech

Innovent eyes China approval after matching Eylea in phase 3

Innovent’s prospect matched Bayer and Regeneron’s Eylea, teeing up filings for Chinese approval of a molecule that could cut maintenance dosing.

Nick Paul Taylor Mar 24, 2026 6:00am

Closeup of blue eye on black background

Kalaris pauses eye drug trial to resolve ocular inflammation

Mar 11, 2026 6:30am

Closeup of blue eye on black background

Preclinical eye disease biotech sets sights on $17M NYSE IPO

Feb 18, 2026 8:55am

IPO initial public offering

Agomab, SpyGlass head to Nasdaq with IPOs totaling $350M

Feb 6, 2026 4:04am

IPO initial public offering Wall Street

Immunology biotech Agomab, eye-focused SpyGlass share IPO plans

Jan 19, 2026 4:50am

eye eyeball eye art

UK biotech eyes $1B deal to deliver eye gene therapy at doctor

Jan 6, 2026 6:25am